{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:18:49Z","timestamp":1787019529968,"version":"build-2736575974"},"reference-count":60,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Burkitt lymphoma (BL) is an aggressive B-cell non-Hodgkin lymphoma that is almost uniformly associated with translocations involving the gene for MYC on chromosome 8. The 3 subtypes of BL, endemic, sporadic, and immunodeficiency-associated, differ from epidemiologic and clinical perspectives but may be genetically similar. Prompt administration of multiagent immunochemotherapy regimens is associated with favorable outcomes for the majority of patients. Survival is inferior in older patients, likely reflecting increased therapy-related toxicity, possibly resulting in decreased treatment intensity. Central nervous system prophylaxis, tumor lysis prevention and treatment, and management of infectious complications from myelosuppressive regimens are critical. Prognosis of refractory or relapsed disease is poor and patients are best treated on clinical trials when available.<\/jats:p>","DOI":"10.1182\/blood-2014-06-538504","type":"journal-article","created":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T03:29:24Z","timestamp":1411702164000},"page":"2913-2920","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":81,"title":["How I treat Burkitt lymphoma in adults"],"prefix":"10.1182","volume":"124","author":[{"given":"Caron","family":"Jacobson","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"197","key":"2019111817441566500_B1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/bjs.18004619704","article-title":"A sarcoma involving the jaws in African children.","volume":"46","author":"Burkitt","year":"1958","journal-title":"Br J Surg"},{"key":"2019111817441566500_B2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/1097-0142(196103\/04)14:2<258::AID-CNCR2820140206>3.0.CO;2-7","article-title":"Malignant lymphoma in African children. I. A clinical syndrome.","volume":"14","author":"Burkitt","year":"1961","journal-title":"Cancer"},{"issue":"6","key":"2019111817441566500_B3","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2141.2011.09013.x","article-title":"Epidemiology: clues to the pathogenesis of Burkitt lymphoma.","volume":"156","author":"Magrath","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111817441566500_B4","first-page":"166","article-title":"Burkitt\u2019s lymphoma in Africa, a review of the epidemiology and etiology.","volume":"7","author":"Orem","year":"2007","journal-title":"Afr Health Sci"},{"issue":"2","key":"2019111817441566500_B5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nrmicro1089","article-title":"Endemic Burkitt\u2019s lymphoma: a polymicrobial disease?","volume":"3","author":"Rochford","year":"2005","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"2019111817441566500_B6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"19","key":"2019111817441566500_B7","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111817441566500_B8","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project.","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111817441566500_B9","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.ejca.2004.09.004","article-title":"Gender and age-related differences in Burkitt lymphoma\u2014epidemiological and clinical data from The Netherlands.","volume":"40","author":"Boerma","year":"2004","journal-title":"Eur J Cancer"},{"issue":"11","key":"2019111817441566500_B10","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"issue":"25","key":"2019111817441566500_B11","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-03-275917","article-title":"AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and\/or biology?","volume":"116","author":"Guech-Ongey","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111817441566500_B12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ijc.2910170108","article-title":"Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas.","volume":"17","author":"Zech","year":"1976","journal-title":"Int J Cancer"},{"issue":"24","key":"2019111817441566500_B13","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","article-title":"Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.","volume":"79","author":"Dalla-Favera","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"2019111817441566500_B14","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1073\/pnas.79.24.7837","article-title":"Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.","volume":"79","author":"Taub","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"2019111817441566500_B15","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt\u2019s lymphoma from transcriptional and genomic profiling.","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111817441566500_B16","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma.","volume":"44","author":"Love","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"2019111817441566500_B17","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"issue":"7418","key":"2019111817441566500_B18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"issue":"7052","key":"2019111817441566500_B19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nature03845","article-title":"Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.","volume":"436","author":"Hemann","year":"2005","journal-title":"Nature"},{"issue":"23","key":"2019111817441566500_B20","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt\u2019s lymphoma.","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111817441566500_B21","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2012-03-415380","article-title":"Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas.","volume":"120","author":"Victora","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111817441566500_B22","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/ni.2428","article-title":"The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry.","volume":"13","author":"Dominguez-Sola","year":"2012","journal-title":"Nat Immunol"},{"issue":"11","key":"2019111817441566500_B23","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/ni.2418","article-title":"The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.","volume":"13","author":"Calado","year":"2012","journal-title":"Nat Immunol"},{"issue":"12","key":"2019111817441566500_B24","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/leu.2011.156","article-title":"The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma.","volume":"25","author":"Lenze","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"2019111817441566500_B25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.semcancer.2009.07.004","article-title":"Burkitt\u2019s lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology.","volume":"19","author":"Rowe","year":"2009","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2019111817441566500_B26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/35095584","article-title":"Epstein-Barr virus: exploiting the immune system.","volume":"1","author":"Thorley-Lawson","year":"2001","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2019111817441566500_B27","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1128\/JVI.02596-07","article-title":"Epstein-Barr virus nuclear antigen 1 does not cause lymphoma in C57BL\/6J mice.","volume":"82","author":"Kang","year":"2008","journal-title":"J Virol"},{"issue":"2","key":"2019111817441566500_B28","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a014282","article-title":"Oncogenic mechanisms in Burkitt lymphoma.","volume":"4","author":"Schmitz","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"2019111817441566500_B29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2141.2003.04238.x","article-title":"Detection by the fluorescence in situ hybridization technique of MYC translocations in paraffin-embedded lymphoma biopsy samples.","volume":"121","author":"Haralambieva","year":"2003","journal-title":"Br J Haematol"},{"key":"2019111817441566500_B30","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Swerdlow","year":"2008"},{"issue":"9","key":"2019111817441566500_B31","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1073\/pnas.83.9.2984","article-title":"Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma.","volume":"83","author":"Pelicci","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019111817441566500_B32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood-2005-01-0168","article-title":"Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas.","volume":"106","author":"Bellan","year":"2005","journal-title":"Blood"},{"key":"2019111817441566500_B33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0065-230X(08)60456-X","article-title":"Immunohistological analysis of human lymphoma: correlation of histological and immunological categories.","volume":"42","author":"Stein","year":"1984","journal-title":"Adv Cancer Res"},{"issue":"14","key":"2019111817441566500_B34","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111817441566500_B35","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V99.3.815","article-title":"De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.","volume":"99","author":"Yamaguchi","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111817441566500_B36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.V90.1.244","article-title":"Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin\u2019s lymphoma.","volume":"90","author":"Gascoyne","year":"1997","journal-title":"Blood"},{"issue":"8","key":"2019111817441566500_B37","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas.","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111817441566500_B38","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non-Hodgkin\u2019s lymphomas: dissimilarities from lymphomas in adults.","volume":"7","author":"Murphy","year":"1980","journal-title":"Semin Oncol"},{"issue":"2","key":"2019111817441566500_B39","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.1989.7.2.186","article-title":"Non-Hodgkin\u2019s lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution.","volume":"7","author":"Murphy","year":"1989","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111817441566500_B40","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111817441566500_B41","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"20","key":"2019111817441566500_B42","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1002\/cncr.28264","article-title":"Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database.","volume":"119","author":"Castillo","year":"2013","journal-title":"Cancer"},{"issue":"24","key":"2019111817441566500_B43","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1182\/blood-2012-12-475558","article-title":"Trends in survival of patients with Burkitt lymphoma\/leukemia in the USA: an analysis of 3691 cases.","volume":"121","author":"Costa","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111817441566500_B44","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdh262","article-title":"Treatment of Burkitt\u2019s\/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens.","volume":"15","author":"Smeland","year":"2004","journal-title":"Ann Oncol"},{"issue":"8","key":"2019111817441566500_B45","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 study.","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111817441566500_B46","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial).","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111817441566500_B47","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.20143","article-title":"Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.","volume":"100","author":"Rizzieri","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"2019111817441566500_B48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.12736","article-title":"Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.","volume":"165","author":"Rizzieri","year":"2014","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111817441566500_B49","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt\u2019s-type adult acute lymphoblastic leukemia.","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111817441566500_B50","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","article-title":"Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.","volume":"16","author":"Divine","year":"2005","journal-title":"Ann Oncol"},{"issue":"20","key":"2019111817441566500_B51","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt\u2019s lymphoma.","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"2019111817441566500_B52","article-title":"Addition of rituximab improves outcome of HIV negative patients with Burkitt lymphom treated with the LMBA protocol: results of the randomized intergroup (GRAALL-Lysa) LMBA02 protocol [abstract].","volume-title":"Blood","author":"Ribrag","year":"2012"},{"issue":"8","key":"2019111817441566500_B53","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt's lymphoma: a retrospective analysis.","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111817441566500_B54","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2141.2006.06080.x","article-title":"Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma.","volume":"133","author":"Song","year":"2006","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111817441566500_B55","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.leu.2403733","article-title":"Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.","volume":"19","author":"van Imhoff","year":"2005","journal-title":"Leukemia"},{"issue":"9","key":"2019111817441566500_B56","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.1996.14.9.2465","article-title":"Adult Burkitt\u2019s and Burkitt-like non-Hodgkin\u2019s lymphoma\u2014outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation.","volume":"14","author":"Sweetenham","year":"1996","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111817441566500_B57","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.27918","article-title":"Dose-intensive chemotherapy including rituximab in Burkitt\u2019s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).","volume":"119","author":"Ribera","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"2019111817441566500_B58","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity.","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2019111817441566500_B59","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.639.639","article-title":"A modified dose intensive R-CODOX-M\/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma (BL) demonstrates high cure rates and low toxicity: prospective multicenter phase II trial of the AIDS Malignancy Consortium (AMC 048).","volume":"122","author":"Noy","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111817441566500_B60","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc.","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/19\/2913\/1380993\/2913.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/19\/2913\/1380993\/2913.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T17:44:39Z","timestamp":1574099079000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/124\/19\/2913\/33277\/How-I-treat-Burkitt-lymphoma-in-adults"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,6]]},"references-count":60,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2014,11,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-06-538504","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,6]]}}}